Diabetes: Patients in Australia, Canada, England, and Scotland were given drugs less likely to improve outcomes, despite the availability of more effective drugs https://t.co/qna94WKM12 https://t.co/vYxDv8R7qE
(BJGP) Tendencia en el uso de antidiabéticos en AP en Australia, Canadá, Escocia e Inglaterra (2012-2017) https://t.co/BUVlMesgx5 Est Observ https://t.co/NVpnReoHa7
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
RT @kamleshkhunti: Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lag…
Study from Canada, England, Scotland and Australia New therapies are displacing sulphonylureas Adoption of SGLT2s lags behind DPP4s But are we using right therapies in appropriate patients? https://t.co/SzHQ6QOG3v https://t.co/DgGYJaIazg
RT @drpatrickholmes: Trends in #type2diabetes medication in 🇨🇦🇦🇺🏴&🏴 2012-2017 metformin ⬇️(except 🇦🇺) sulfonylurea⬇️⬇️ (except…
RT @drpatrickholmes: Trends in #type2diabetes medication in 🇨🇦🇦🇺🏴&🏴 2012-2017 metformin ⬇️(except 🇦🇺) sulfonylurea⬇️⬇️ (except…
Marketing and not research. DPP4i’s should decrease. Metformin should increase.
RT @drpatrickholmes: Trends in #type2diabetes medication in 🇨🇦🇦🇺🏴&🏴 2012-2017 metformin ⬇️(except 🇦🇺) sulfonylurea⬇️⬇️ (except…
RT @drpatrickholmes: Trends in #type2diabetes medication in 🇨🇦🇦🇺🏴&🏴 2012-2017 metformin ⬇️(except 🇦🇺) sulfonylurea⬇️⬇️ (except…
Trends in #type2diabetes medication in 🇨🇦🇦🇺🏴&🏴 2012-2017 metformin ⬇️(except 🇦🇺) sulfonylurea⬇️⬇️ (except🏴🤔) DPP4i ⬆️⬆️ SGLT2i⬆️⬆️ GLP-1ra⬆️ https://t.co/4jpFYfkDYL https://t.co/bvrZCACm7P